Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Health-care companies rose after strong earnings from one obesity-drug maker. Eli Lilly shares rose after it reiterated its forecast for 32% 2025 revenue growth, amid rising demand for its Zepbound ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Comments: Growth in the quarter was driven by Mounjaro, with sales up 60% to $3.5 billion, and Zepbound, with sales of $1.9 billion. New Products revenue, which consists of Ebglyss, Jaypirca, Kisunla, ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

Eli Lilly earnings topped Q4 views with 2025 guidance above consensus, even though Zepbound and Mounjaro slightly missed. Eli Lilly stock rose.

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...